From cost containment to supply resilience: Japan’s evolving policy architecture for generic medicines

Generic medicines policy has long been framed around access and cost containment, but persistent shortages have made continuity of supply an equally pressing concern. This article examines how stable supply has entered Japan’s drug-pricing policy for generic medicines, focusing on four components of the FY2026 drug-pricing reform: minimum prices, basic medicines, unprofitable-product repricing, and the stable-supply manufacturer evaluation. Drawing on official Ministry of Health, Labour and Welfare and Central Social Insurance Medical Council documents, the study distinguishes routine supply sustainability — maintaining production under normal operating conditions — from disruption resilience, examined through four dimensions: dependence, substitutability, inventory, and time to recover. Each measure is assessed at three functional levels: recognition of a vulnerability, support for a supply condition, and secured capacity. All four measures support routine supply sustainability. Only two extend further. Unprofitable-product repricing recognizes difficulty in securing alternative supply, and the manufacturer evaluation rewards additional supply when another company’s product is subject to restricted or suspended shipment. None secures replacement capacity, inventory, or recovery time in advance. The article describes this development as resilience-aware pricing, distinguishes it from resilience procurement, and argues that the connection between pricing measures and Japan’s separate supply-security framework is now the central design question.